APOC3 and pancreatic neoplasm: The combination of ApoAII-2 and ApoCIII-0 (ApoAII-2+CIII-0) was able to detect 66.1% (160/242) of pancreatic cancer patients relative to healthy individuals (Table S5) at a cut-off value [189 arbitrary units (AU)] that had been arbitrarily determined to obtain a specificity of 95% or higher [97.5% (115/118)].